dm+d

Unassigned

New Medicines

Type 2 diabetes mellitus in adults

Information

New formulation
Novo Nordisk
Novo Nordisk

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A once-weekly, fixed-dose combination product comprising of insulin icodec (a long-acting basal insulin analogue with a terminal half-life of approximately 196 hour) and semglutide (glucagon-like peptide-1 analogue)
More than 4.9 million people in the UK have diabetes. 850,000 people are currently living with type 2 diabetes but are yet to be diagnosed and 13.6 million people are now at increased risk of type 2 diabetes in the UK [1].
Type 2 diabetes mellitus in adults
Subcutaneous injection